It's called the IsoPSA. It's being developed by the Cleveland Clinic, the Cleveland VA Medical Center, and other hospitals.
[Ads /]
In tests, it was more accurate than the standard PSA in two ways: identifying cancer versus benign conditions and finding more aggressive forms of prostate cancer.
Blood is drawn, just like a regular PSA.
But in the lab, instead of measuring PSA protein levels, it looks for molecular changes in the protein specific to prostate cancer.
If the results hold up in bigger trials, it could substantially reduce the need for biopsies.
And that would lower the risk of over-treating non-lethal prostate cancer.
[Ads /]
----------
Send a breaking news alert
Report a correction or typo
Learn more about the 6abc apps